Formulation: A solid
Formal Name: (6α,11β,16α,17α)-6,9-difluoro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-3-oxo-androsta-1,4-diene-17-carbothioic acid, S-(fluoromethyl) ester
Purity: ≥98%
Formula Markup: C27H29F3O6S
Formula Weight: 538,6
Shelf life (days): 1460
CAS Number: 397864-44-7
Notes: Fluticasone furoate is a synthetic glucocorticoid.{53493} It is selective for the glucocorticoid receptor over the mineralocorticoid, progesterone, and androgen receptors in reporter assays (EC50s = 0.03, 23.4, 0.9, and >10,000 nM, respectively), as well as estrogen receptor α (ERα) and ERβ in scintillation proximity assays (EC50s = >10,000 nM for both). Fluticasone furoate reduces LPS-induced increases in TNF-α production in human peripheral blood mononuclear cells (PBMCs) with an EC50 value of 0.12 nM. It decreases S. aureus enterotoxin-induced increases in IFN-γ, IL-2, IL-5, IL-17, and TNF-α levels in patient-derived nasal polyp tissue when used at a concentration of 100 nM.{53494} Intrathecal administration of fluticasone furoate (30 µg/animal) reduces ovalbumin-induced increases in bronchoalveolar lavage fluid (BALF) eosinophil infiltration in a rat model of allergic inflammation.{53493} Formulations containing fluticasone furoate have been used in the treatment of seasonal allergies.
English
Deutsch
